Development and Characetization of Calcium Channel Blocker (Nifedipine) by Sublingual Drug Delivery System
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 10 No. 2 (2022): 2022 Volume - 10 Issue - 2
Abstract
Sublingual tablet of oral formulations of these drugs have been developed to improve their acceptability to patients and thus improve compliance. The focus of present investigation was to improve solubility, bioavailability and to achieved rapid onset action sublingual tablets of Nifedipine were prepared by direct compression technique. Eight Formulations were formulated using sodium starch glycolate and crosscaramellose as superdisintegrants on Friability, Disintegration time. In addition, the prepared tablets were also evaluated for weight variation, thickness, diameter, friability, content uniformity, wetting time and drug release studies. Formulation reveals fast dissolution and disintegration rate of optimized Nifedipine sublingual tablet, which is prerequisite for rapid management of angina.
Keywords
Nifedipine, direct compression technique, FTIR studies, Excipient, Drug release studies.
1.
H.Parameshwar, Shaik maviya azhar patel, A.V. Jithan. Development and Characetization of Calcium Channel Blocker (Nifedipine) by Sublingual Drug Delivery System . Int. J. of Allied Med. Sci. and Clin. Res. [Internet]. 2022 Jul. 4 [cited 2025 Nov. 6];10(2):261-7. Available from: https://ijamscr.com/ijamscr/article/view/1214
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
References
-
1. Chasseaud LF, Darragh A, Doyle E, Lambe RF, Taylor T. Isosorbide dinitrate plasma concentration and bioavailability in human subjects after administration of standard oral and sublingual formulations. J Pharm Sci. 1984;73(5):699-701. doi: 10.1002/jps.2600730530, PMID 6737249.
2. Jiménez-castellanos MR, Zia H, Rhodes CT. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm. 1993;19(1-2):143-94. doi: 10.3109/03639049309038765.
3. Labhade S, Malode C, Rawal V, Rupvate S.et al. Review article on sublingual drug delivery system. 2019;9(3): https://doi.org/10.22270/jddt.v9i3.2684
4. Lachman L, Liberman A, King JL. Tablets: the theory and practice of industrial pharmacy. Varghese publishing house. 1987. 3rd ed: pp. 296-300.
5. Sanada H, Yonezawa Y, Danjo K. Preparation and evaluation of compressed tablet rapidly disintegrating in the oral cavity [Chemistry Pharma bulletin]. 1996;44(1):2121-7.
6. Biradar SS, Bhagavaati ST, Kuppasad IJ. Fast dissolving drug delivery systems: a brief overview. Int J Pharmacol. 2006;4(1):22-7.
7. Bhanji NH, Chouinard GA, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol. 2004;14(2):87-92. doi: 10.1016/S0924-977X(03)00109-3.
8. Chue P, Welch R, Binder C. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Can J Psychiatry. 2004; 49(10):701-3. doi: 10.1177/070674370404901009, PMID 15560318.
9. Sherwood BE et al., design, prepare and in vitro evaluation of tablets. Pharm Res. 1996;13(9):S197.
10. Smart JD, Formulated sublingual tablets. Rev. 2004; 56:481-9.
11. Susanne B, Margareta D, Bo L, Hans L, Anders P, Marie W et al.. design, prepare and characterization of acyclovir sublingual tablets. IJPASR sci. 2003;20:327-34.
12. Vanjan MR. Research article on sublingual tablets of Rosiglitazone J. Pharm Sci. 2012; 1973(62).
13. Vaasu EM et al. development of sustained release of Atenelol sublingual tablets. Drug Dev Ind Pharm. 1980;6:291-309.
References
1. Chasseaud LF, Darragh A, Doyle E, Lambe RF, Taylor T. Isosorbide dinitrate plasma concentration and bioavailability in human subjects after administration of standard oral and sublingual formulations. J Pharm Sci. 1984;73(5):699-701. doi: 10.1002/jps.2600730530, PMID 6737249.
2. Jiménez-castellanos MR, Zia H, Rhodes CT. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm. 1993;19(1-2):143-94. doi: 10.3109/03639049309038765.
3. Labhade S, Malode C, Rawal V, Rupvate S.et al. Review article on sublingual drug delivery system. 2019;9(3): https://doi.org/10.22270/jddt.v9i3.2684
4. Lachman L, Liberman A, King JL. Tablets: the theory and practice of industrial pharmacy. Varghese publishing house. 1987. 3rd ed: pp. 296-300.
5. Sanada H, Yonezawa Y, Danjo K. Preparation and evaluation of compressed tablet rapidly disintegrating in the oral cavity [Chemistry Pharma bulletin]. 1996;44(1):2121-7.
6. Biradar SS, Bhagavaati ST, Kuppasad IJ. Fast dissolving drug delivery systems: a brief overview. Int J Pharmacol. 2006;4(1):22-7.
7. Bhanji NH, Chouinard GA, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol. 2004;14(2):87-92. doi: 10.1016/S0924-977X(03)00109-3.
8. Chue P, Welch R, Binder C. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Can J Psychiatry. 2004; 49(10):701-3. doi: 10.1177/070674370404901009, PMID 15560318.
9. Sherwood BE et al., design, prepare and in vitro evaluation of tablets. Pharm Res. 1996;13(9):S197.
10. Smart JD, Formulated sublingual tablets. Rev. 2004; 56:481-9.
11. Susanne B, Margareta D, Bo L, Hans L, Anders P, Marie W et al.. design, prepare and characterization of acyclovir sublingual tablets. IJPASR sci. 2003;20:327-34.
12. Vanjan MR. Research article on sublingual tablets of Rosiglitazone J. Pharm Sci. 2012; 1973(62).
13. Vaasu EM et al. development of sustained release of Atenelol sublingual tablets. Drug Dev Ind Pharm. 1980;6:291-309.
2. Jiménez-castellanos MR, Zia H, Rhodes CT. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm. 1993;19(1-2):143-94. doi: 10.3109/03639049309038765.
3. Labhade S, Malode C, Rawal V, Rupvate S.et al. Review article on sublingual drug delivery system. 2019;9(3): https://doi.org/10.22270/jddt.v9i3.2684
4. Lachman L, Liberman A, King JL. Tablets: the theory and practice of industrial pharmacy. Varghese publishing house. 1987. 3rd ed: pp. 296-300.
5. Sanada H, Yonezawa Y, Danjo K. Preparation and evaluation of compressed tablet rapidly disintegrating in the oral cavity [Chemistry Pharma bulletin]. 1996;44(1):2121-7.
6. Biradar SS, Bhagavaati ST, Kuppasad IJ. Fast dissolving drug delivery systems: a brief overview. Int J Pharmacol. 2006;4(1):22-7.
7. Bhanji NH, Chouinard GA, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol. 2004;14(2):87-92. doi: 10.1016/S0924-977X(03)00109-3.
8. Chue P, Welch R, Binder C. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Can J Psychiatry. 2004; 49(10):701-3. doi: 10.1177/070674370404901009, PMID 15560318.
9. Sherwood BE et al., design, prepare and in vitro evaluation of tablets. Pharm Res. 1996;13(9):S197.
10. Smart JD, Formulated sublingual tablets. Rev. 2004; 56:481-9.
11. Susanne B, Margareta D, Bo L, Hans L, Anders P, Marie W et al.. design, prepare and characterization of acyclovir sublingual tablets. IJPASR sci. 2003;20:327-34.
12. Vanjan MR. Research article on sublingual tablets of Rosiglitazone J. Pharm Sci. 2012; 1973(62).
13. Vaasu EM et al. development of sustained release of Atenelol sublingual tablets. Drug Dev Ind Pharm. 1980;6:291-309.